UKONIQ

Peak

umbralisib tosylate

TG Therapeutics
NDAORALTABLETPriority Review
Approved
Feb 2021
Lifecycle
Peak
Competitive Pressure
0/100

Loss of Exclusivity

LOE Date
May 26, 2035
112 months away
Patent Expiry
May 26, 2035
Exclusivity Expiry
Feb 5, 2026

Patent Records (5)

Patent #ExpiryTypeUse Code
10072013
Jul 2, 2033
U-3064
10981919
Jul 2, 2033
U-3064
9150579
Jul 2, 2033
SubstanceProduct
—
9669033
Jul 2, 2033
U-3064
10570142
Jul 2, 2033
SubstanceProduct
U-3063
Company
TG Therapeutics
TG Therapeutics
NEW YORK, NY
15 open jobs
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers